NVision Medical

The company's primary focus was the development of devices for the in-office diagnosis of conditions such as fallopian tube blockages, a leading cause of infertility, and the early detection of ovarian cancer. Its main product was a microcatheter-based device, the first and only one cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes. This technology offered a platform for earlier diagnosis of ovarian cancer, as recent studies have shown that many types of this cancer originate in the fallopian tubes. The device was designed for use in a gynecologist's office without requiring incisions or general anesthesia.

After successfully developing its core technology and gaining FDA clearance, NVision Medical was acquired by Boston Scientific in April 2018. The acquisition involved an upfront payment of $150 million, with potential for an additional $125 million based on clinical and commercial milestones. The acquisition was seen as a strategic move for Boston Scientific to expand its women's health portfolio, with plans to conduct further clinical research to solidify the diagnostic capabilities of the nVision device. Following the acquisition, Sarna planned to remain with the company to continue advancing the product's development and reach.